


1/18
Fig. 1






BEST AVAILABLE COPY

10/531543
PCT/KR2004/002190
RO/KR 00.00.0000


2/18
Fig. 2

SK-N-SH



3/18
Fig. 3


Annexin assay



4/18
Fig. 4


FACS Analysis

pEGFP-C2



15.97%


pEGFP-Cp




27.03%

48h

5/18
Fig. 5



6/18
Fig. 6




24h after transfection

10/531543


7/18

Fig. 7




8/18
Fig. 8

A




B



10/531543

9/18

Fig. 9



HA/WNV-Cp	+	+	+
Flag-Jab 1	-	+	+
LLnL (20 uM/mL)	-	-	+


PCT/KR2004/002190

RO/KR 00.00.0000

10/531543


10/18

Fig. 10




PCT/KR2004/002190
RO/KR 00.00.0000
10/531543

11/18
Fig. 11




12/18
Fig. 12



13/18

Fig. 13




PCT/KR2004/002190

RO/KR 00.00.0000

10/531543

14/18

Fig. 14




PCT/KR2004/002190

RO/KR 00.00.0000

10/531543


15/18

Fig. 15



16/18

Fig. 16




PCT/KR2004/002190

RO/KR 00.00.0000

10/531543

17/18

Fig. 17



10/531543

18/18

Fig. 18

Control Retrovirus
 stable cell line

